Real-world analysis of treatment patterns and clinical outcomes in patients with newly diagnosed chronic lymphocytic leukemia from seven Latin American countries

Autor:	Luis Palmer, Sergio Araujo, Alvaro Gomez Diaz, David Gómez-Almaguer, Carlos S. Chiattone, Yen-Wen Chen, Lori Parisi, Danielle Leão Cordeiro de Farias, Carolina Pavlovsky, Kenny Mauricio Galvez-Cardenas, Michelle Mahler, Gerardo Machnicki, Ana Lisa Basquiera, Paula Barreyro, Elena J Tuna-Aguilar, Jennifer H. Lin
Rok vydání:	2020
Předmět:	Male medicine.medical_specialty Latin Americans Chronic lymphocytic leukemia Newly diagnosed Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Risk Factors hemic and lymphatic diseases Chart review Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans In patient Progression-free survival neoplasms Aged Chlorambucil business.industry Age Factors Hematology Middle Aged medicine.disease Leukemia Lymphocytic Chronic B-Cell Fludarabine Survival Rate Latin America 030220 oncology & carcinogenesis Female business 030215 immunology medicine.drug
Zdroj:	Hematology (Amsterdam, Netherlands). 25(1)
ISSN:	1607-8454
Popis:	To describe chronic lymphocytic leukemia (CLL) treatment patterns and patient outcomes in Latin America.This chart review study (NCT02559583; 2008-2015)evaluated time to progression (TTP) and overall survival (OS) outcomes among patients with CLL who initiate done (The most commonly prescribed therapies in both LOTs were chlorambucil-, followed by fludarabine- and cyclophosphamide (C)/CHOP-based therapies. Chlorambucil- and C/CHOP-based therapies were largely prescribed to elderly patients (≥65 years) while fludarabine-based therapy was predominantly used by younger patients (≤65 years). In LOT1, relative to chlorambucil-administered patients, those prescribed fludarabine-based therapies had lower risk of disease progression (hazard ratio [HR] and 95% confidence interval [CI] 0.32 [0.19-0.54]), whereas C/CHOP-prescribed patients had higher risk (HR 95%CI 1.88 [1.17-3.04]). Similar results were observed in LOT2. There was no difference in OS between treatments in both LOTs.Novel therapies such as kinase inhibitors were rarely prescribed in LOT1 or LOT2in Latin America. The greater TTP observed forfludarabine-based therapies could be attributed to the fact that fludarabine-based therapies are predominantly administered to young and healthy patients.Chlorambucil-based therapy, which has limited benefits, is frequently prescribed in Latin America. Prescribing novel agents for fludarabine-based therapy-ineligible patients with CLL is the need of the hour.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1cd5821bcec2d08c5acfe0f56a20753 https://pubmed.ncbi.nlm.nih.gov/33095117 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.